STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

MBRX MOLECULIN BIOTECH INCORPORATED StockScouter® Report

4

StockScouter® Score

MOLECULIN BIOTECH INCORPORATED, a micro cap company in the healthcare sector, is expected to underperform the market over the next six months with slightly higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • Moving average analysis for MBRX suggests weak price movement over the medium term. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 80% done.
Progress: 20% done.
Low
High

Core Model Grades

F
N/A
N/A
D

Previous Ratings